Zentalis Pharmaceuticals【ZNTL】銘柄情報

Zentalis Pharmaceuticals Inc (ZNTL) 銘柄情報

個人投資家向けのプロ仕様のツール。

プレミアム

通貨

3.60

( - )

買値

3.41

売値

3.78

出来高

0.00 日の範囲 0.00

1.13 52 週間の範囲 6.95

時価総額

256.271M

前日終値

3.60

始値

時刻

3.51

最終取引時間

17:40:49

財務取引量

VWAP

平均取引量 (3 か月)

US$ 1,964,636

発行済株式数

71,186,348

配当利回り

PER

-2.47

1 株当たり利益 (EPS)

-1.74

歳入

純利益

-124.13M

Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers in the United States. It develops azenosertib, which is in a Phase 3 clinical trial for the treatment of ovarian cancer a... Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers in the United States. It develops azenosertib, which is in a Phase 3 clinical trial for the treatment of ovarian cancer and other tumor types. The company also develops ZN-c3-001, a phase 1 study that evaluated azenosertib monotherapy in solid tumors; and MAMMOTH (ZN-c3-006) is a Phase 1/2 clinical trial of azenosertib in patients with PARP-inhibitor resistant ovarian cancer. It has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC. Zentalis Pharmaceuticals, Inc. was incorporated in 2014 and is based in San Diego, California. 詳細を表示

セクター

Healthcare

業界

Biotechnology & Life Sciences

ウェブサイト

zentalis.com

本社

San Diego, United States

設立

2026

Zentalis Pharmaceuticals Inc is listed in the Healthcare sector of the ナスダック市場 with ticker ZNTL. The last closing price for Zentalis Pharmaceuticals was US$3.60. Over the last year, Zentalis Pharmaceuticals shares have traded in a share price range of US$ 1.13 to US$ 6.95.

Zentalis Pharmaceuticals currently has 71,186,348 shares in issue. The market capitalisation of Zentalis Pharmaceuticals is US$256.27 million. Zentalis Pharmaceuticals has a price to earnings ratio (PE ratio) of -2.47.

Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SAN DIEGO, June 01, 2026 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical...

Form 4 - Statement of changes in beneficial ownership of securities

Form 3 - Initial statement of beneficial ownership of securities

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Form 8-K - Current report

Zentalis Strengthens Commercial Leadership with Appointments of Shannon Campbell to Board of Directors and Sarah Kelly as SVP of Commercial Strategy

Appointments enhance commercialization readiness as Zentalis advances registrational program for azenosertib in...

Zentalis Pharmaceuticals to Present Phase 1b MUIR Trial Data Showing Encouraging Clinical Activity and Manageable Safety Profile of Azenosertib Plus Paclitaxel in Platinum-Resistant Ovarian Cancer at ASCO 2026

In an all-comer PROC population, across multiple dose cohorts, manageable safety profile of the combination was...

期間 †	前日比	前日比 %	始値	高値	安値	平均出来高	VWAP
1	-0.13	-3.48525469169	3.73	3.965	3.42	618798	3.66298731	CS
4	-0.72	-16.6666666667	4.32	4.39	3.42	1003940	3.84303901	CS
12	1.13	45.7489878543	2.47	6.95	2.07	2064469	5.10209861	CS
26	2.17	151.748251748	1.43	6.95	1.31	1647926	4.06576773	CS
52	1.97	120.858895706	1.63	6.95	1.13	1214823	3.20365983	CS
156	-20.2	-84.8739495798	23.8	30.53	1.01	1192124	6.17893552	CS
260	-52.28	-93.5576234789	55.88	87.19	1.01	931498	12.30450581	CS